Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Ibrutinib and Rituximab in Refractory/Relapsed PCNSL
NCT04421560Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2020
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, ibrutinib, rituximab in primary central nervous system lymphoma (PCNSL), sponsored by Dana-Farber Cancer Institute. Started Aug 2020; status: recruiting.
02
Drugs
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04421560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04421560.